Ken Griffin C4 Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 48,900 shares of CCCC stock, worth $314,427. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,900

Previous 53,600 8.77%

Holding current value

$314,427

Previous $437,000 48.51%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.05 - $8.1 $158,512 - $317,025	39,139 Added 11.7%	373,657 $1.73 Million
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $1.52 Million - $3.16 Million	287,304 Added 608.51%	334,518 $2.73 Million
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $409,139 - $2.09 Million	-346,728 Reduced 88.01%	47,214 $266,000
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $498,727 - $1.07 Million	-275,540 Reduced 41.16%	393,942 $732,000
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $391,402 - $536,576	142,328 Added 27.0%	669,482 $1.84 Million
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $457,727 - $1.33 Million	147,654 Added 38.91%	527,154 $1.66 Million
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $1.35 Million - $2.56 Million	249,713 Added 192.4%	379,500 $2.24 Million
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $817,743 - $1.3 Million	101,836 Added 364.34%	129,787 $1.14 Million
Q2 2022 Aug 15, 2022	SELL	$5.06 - $26.46 $406,206 - $2.12 Million	-80,278 Reduced 74.17%	27,951 $211,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $1.07 Million - $1.79 Million	-53,727 Reduced 33.17%	108,229 $2.63 Million
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $3.57 Million - $5.7 Million	121,621 Added 301.53%	161,956 $5.21 Million
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $2.53 Million - $3.56 Million	-70,443 Reduced 63.59%	40,335 $1.8 Million
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $2.75 Million - $3.82 Million	90,527 Added 447.02%	110,778 $4.19 Million
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $2.67 Million - $3.89 Million	-83,622 Reduced 80.5%	20,251 $749,000
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $2.37 Million - $3.85 Million	103,873 New	103,873 $3.44 Million

Others Institutions Holding CCCC

# of Institutions

119

Shares Held

53.8M

Call Options Held

331K

Put Options Held

145K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $315M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account